Reliance Life Sciences
Biosimilar developer, India. 14 development products across 14 molecules: adalimumab, bevacizumab, darbepoetin alfa, denosumab, etanercept, follitropin alfa, golimumab, infliximab, omalizumab, ranibizumab, rituximab, somatropin, trastuzumab, ustekinumab.
About Reliance Life Sciences
Reliance Life Sciences holds more Indian biosimilar permissions than any other company: fourteen molecules, from follitropin in 2010 to golimumab and ustekinumab in 2023. It was the first company in the world to receive permissions for bevacizumab, golimumab and omalizumab, and the first domestic Indian maker of infliximab. All of its products are sold in India, and none has yet been filed with the regulators in the United States, Europe, Japan, Canada or the Gulf. Its ustekinumab, UstekiRel, is one of the few Indian permissions where the published record names the brand.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Adalimumab | Reliance Life Sciences adalimumab | · | · | · | · | · | Jun 2015 | · | 1/7 |
| Bevacizumab | Reliance Life Sciences bevacizumab | · | · | · | · | · | Jan 2016 | · | 1/7 |
| Darbepoetin alfa | Reliance Life Sciences darbepoetin alfa | · | · | · | · | · | Jun 2016 | · | 1/7 |
| Denosumab | Reliance Life Sciences denosumab | · | · | · | · | · | Dec 2022 | · | 1/7 |
| Etanercept | Reliance Life Sciences etanercept | · | · | · | · | · | May 2018 | · | 1/7 |
| Follitropin alfa | Reliance Life Sciences follitropin alfa | · | · | · | · | · | Apr 2010 | · | 1/7 |
| Golimumab | Reliance Life Sciences golimumab | · | · | · | · | · | Apr 2023 | · | 1/7 |
| Infliximab | Reliance Life Sciences infliximab | · | · | · | · | · | Mar 2014 | · | 1/7 |
| Omalizumab | Reliance Life Sciences omalizumab | · | · | · | · | · | Feb 2020 | · | 1/7 |
| Ranibizumab | Reliance Life Sciences ranibizumab | · | · | · | · | · | Mar 2020 | · | 1/7 |
| Rituximab | Reliance Life Sciences rituximab | · | · | · | · | · | Feb 2015 | · | 1/7 |
| Somatropin | Reliance Life Sciences somatropin | · | · | · | · | · | May 2018 | · | 1/7 |
| Trastuzumab | Reliance Life Sciences trastuzumab | · | · | · | · | · | Jun 2015 | · | 1/7 |
| Ustekinumab | UstekiRel | · | · | · | · | · | Apr 2023 | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Reliance Life Sciences is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Epoetin alfa and zeta | Reliance Biopharmaceuticals (INN only) | CDSCO | Reliance Biopharmaceuticals | Jan 2008 | Not stated in the CDSCO list |
Companies on the same molecules
Developers whose portfolios overlap most with Reliance Life Sciences, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCOApr 2010Reliance Life Sciences (INN only), follitropin alfa
- CDSCOMar 2014Reliance Life Sciences (INN only), infliximab
- CDSCOFeb 2015Reliance Life Sciences (INN only), rituximab
- CDSCOJun 2015Reliance Life Sciences (INN only), trastuzumab
- CDSCOJun 2015Reliance Life Sciences (INN only), adalimumab
- CDSCOJan 2016Reliance Life Sciences (INN only), bevacizumab
- CDSCOJun 2016Reliance Life Sciences (INN only), darbepoetin alfa
- CDSCOMay 2018Reliance Life Sciences (INN only), etanercept
- CDSCOMay 2018Reliance Life Sciences (INN only), somatropin
- CDSCOFeb 2020Reliance Life Sciences (INN only), omalizumab
- CDSCOMar 2020Reliance Life Sciences (INN only), ranibizumab
- CDSCODec 2022Reliance Life Sciences (INN only), denosumab
- CDSCOApr 2023Reliance Life Sciences (INN only), golimumab
- CDSCOApr 2023UstekiRel, ustekinumab
Compare Reliance Life Sciences with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant